Pricing updated 2019-04-24. Prices are subject to change without notice.
CFI-400945 is an orally available, selective inhibitor of polo-like kinase 4 (PLK4; IC50 = 2.8 nM), a unique kinase that regulates centriole duplication during the cell cycle.1 It does not inhibit other members of the PLK family (IC50s > 50 µM for PLK1, PLK2, and PLK3).1 CFI-400945 has been shown to dysregulate centriole duplication, disrupt mitosis, and induce apoptosis in various PLK4-overexpressing breast cancer cells and to reduce tumor growth in mice bearing MDA-MB-468 breast tumor xenografts.1
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
Mason, J.M., Lin, D.C., Wei, X., et al. Functional characterization of CFI-